Virtual Library

Start Your Search

Hongbing Liu

Author of

  • +

    P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.01-90 - A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC) (ID 13105)

      16:45 - 18:00  |  Author(s): Hongbing Liu

      • Abstract
      • Slides


      Apatinib is a new tyrosine kinase inhibitor against vascular endothelial growth factor receptor 2 and improves outcomes in patients (pts) with metastatic gastric cancer as a third line of treatment. Recently, it has been reported effective as third- or later-line treatment in advanced NSCLC. This prospective study tried to assess the efficacy and safety of apatinib combined with DTX as second-line treatment of EGFR negative NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      In this open-label single-arm study, pts recived oral apatinib (500mg, p.o. qd) with DTX(60mg/m2,i.v. d1 q3w) as second-line therapy. The primary endpoint was progression-free-survival (PFS) and the tumor response was determined according to the RECIST 1.1. Treatment was continued until disease progression, death, or intolerable toxicity.

      4c3880bb027f159e801041b1021e88e8 Result

      Between September 2016 and April 2018, 27 pts were enrolled. In 27 pts, there were 23 pts available for efficiency evaluation and 27 pts available for safety evaluation. In the first evaluation of efficacy at one month, computed tomography scan evaluation revealed that partial response (PR) occurred in 7 of 23 pts and other 15 showed stable disease (SD). The median PFS was 4.0667 months (95% CI: 2.5333–6.3333 months). The median OS was 10.5667 months (95% CI: 10.5667– ~ months). The objective response rate(ORR) was 30.43% and disease control rate(DCR) was as high as 95.65 %. Most of the adverse reactions (AEs) were at grade 1 or 2. The grade 3 AEs were hypertension (n=12, 44.44%), hand-foot syndrome (n=3, 11.11%), diarrhea (n=2, 7.41%), mouth ulceration (n=3, 11.11%), thrombocytopenia (n=1, 3.70%). No grade 4 AE or drug-related mortality occurred.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Apatinib has a potential application prospect in second-line therapy combined with DTX for EGFR negative NSCLC pts. The research team will continue the study.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.